AI assistant
Sending…
Celldex Therapeutics, Inc. — Director's Dealing 2017
Jun 16, 2017
31801_dirs_2017-06-16_1702fd4c-8a92-4e19-ad17-51cba95791d0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2017-06-15
Reporting Person: Crowley Elizabeth (Sr. VP &CPDO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-15 | Incentive Stock Option (right to buy) | $2.32 | A | 82000 | Acquired | 2027-06-15 | Common Stock (82000) | Direct |
Footnotes
F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.
F2: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
More from Celldex Therapeutics, Inc.
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 1
Major Shareholding Notification
2026
Mar 26